model housekeep alc
make sever adjust model bring forecast better in-line
commentari guidanc alc includ recent refi account chang
net reduct lower
ebitda margin expans take ep
 year gm ramp steeper lower
higher overal ep unchang
alc adjust revis account rule recap ep per share
shift adj ep estim prior reflect two non-oper
item recent debt refi adopt ifr leas account cap
structur side alc recent price senior note
retir short-term debt june
gener purpos newli issu debt carri blend rate point
total annual interest cost post refin prior run-rat
due lower total amount outstand leas account co adopt
ifr jan among item shift portion annual oper
leas cost interest expens line exit ifr shift result
addit interest cost record annual basi
cost previous capit henc margin line impact
lower oper margin expans ebitda go ep
review updat model base commentari compani call
compani note expect ebitda margin expans
previous includ adjust model bring in-line guidanc
reflect ebitda margin chang take ep
estim ebitda forecast remain ep estim
full year ep vs
adjust gm outlook better align compani commentari adjust
gross margin assumpt better align commentari compani
call model om also point
lower vs compani expect rang
full year suggest adjust model accordingli
adjust lower ep though full year remain
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
mm estim exclud one-tim item
pleas see import disclosur inform page report
alc thesi recap increasingli good beyond setup face volatil still stick behind driver buy thesi
launch panoptix us launch contact len manufactur margin gain start take shape follow
increas return form acceler top-lin growth margin expans ep leverag cycl evolv
driver us approvals/launch occur aug-sept time-frame suggest could see
earli albeit small contribut year-end two launch expect faster uptak panoptix base survey
work earlier year link posit feedback cataract surgeon recent ascr meet june
pleas see import disclosur inform page report
edecmarjunsepdecdecmarjunsepdecdecdecdecdecdectot growth good gross margin expens oper oper oper incom oper margin financi incom loss tax expens rate incom item pre-tax oper incom incom ep fulli outstand outstand exhibit alc revenu model
pleas see import disclosur inform page report
pleas see import disclosur inform page report
enet intang adjustedtot op expens ex amort expens net expens net incom loss continu oper intang exhibit revenu model
pleas see import disclosur inform page report
ereport revenueunit stateslow unit state globallow sale continu compani report compani constant currenc compani organ compani pro-forma revenu growthunit stateslow unit globallow global exhibit incom statement
pleas see import disclosur inform page report
edec cost cost cost gross margin expens research gener oper incom margin incom incom loss share wright medic group
continu strong organ growth extrem
simplic share gain next year
peak augment sale
expens continu run high weigh
modest level debt servic next month
pt ev/sal combin pro-forma
continu strong organ growth extrem
simplic share gain next year
peak augment sale
expens continu run high weigh
pt ev/sal combin pro-forma
revenu target prove aggress either due
slowdown extrem higher dis-synergi
larger anticip payment
slower uptak augment biolog slower uptak
simplic upper extrem
pt ev/sal combin pro-forma
buy thesi predic compani
largest pure-play extrem supplier upper
lower fastest grow segment
global orthoped market growth hip knee
spine versu extrem
given share scale extrem track
record current ceo rob palmisano see
compani posit attract take-out
candid larger orthoped compani
view differenti base deep
dive work shoulder implant market
salesforc product guidanc updat
clinic updat augment rotat cuff graft
buysid sell-sid announc
close transact
pleas see import disclosur inform page report
estim global net patient addit
despit competit abbott
tailwind medicar reimburs felt throughout
revenu growth driven new patient add
price target deriv use
growth exceed driven increas patient
add competit less impact fear
clinic data drive increas usag type
price target deriv use multipl
revenu growth slow fewer patient
addit well defect user base
product delay due regulatori pathway
libr take signific share
price target deriv use multipl lower
preval type diabet continu
increas larg driven demograph
increas focu lower cost treat
diabet improv technolog use
novel devic like cgm grow
face increas competit
sole focu cgm continu product
signific player market
compani
updat google/verili type product
approv launch artifici pancrea
approv launch tandem artifici pancrea
pleas see import disclosur inform page report
estim exclud one-tim item
compound-annual-growth-rate surgic driven launch panoptix
implant vitreoretin equip
compound-annual-growth-rate contact lens support
gm expans vision
larg scale initi lrp
acceler debt servic share buyback near-
compound-annual-growth-rate surgic driven launch panoptix
assum share gain at-iol
compound-annual-growth-rate contact lens support
assum share gain
gm expans vision
one larg scale transact initi lrp
excess capit post alloc share buyback
compound-annual-growth-rate surgic limit uptak
panoptix due cost/reimburs barrier
compound-annual-growth-rate contact lens limit uptak
share loss daili
delay vision manufactur beyond
larg scale initi lrp prove
acceler debt servic share buyback near-
buy thesi predic potenti signific
ep acceler initi lrp
differenti base proprietari
survey work inclus cataract surgeon
explor demand panoptix consum len
explor demand
driver ep acceler outlook better
industri fundament ophthalmolog versu
at-iol revenu upsid sihi
daili len margin expans vision
manufactur modern non-oper
pleas see import disclosur inform page report
